Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Number of holders
-
4
-
Total 13F principal, excl. options
-
9.72M
-
Principal change
-
-87.2M
-
Total reported value, excl. options
-
$10.1M
-
Value change
-
-$86.5M
-
Number of buys
-
1
-
Number of sells
-
-15
-
Price
-
$1.00
Significant Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q2 2023
18 filings reported holding 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q2 2023.
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 has 4 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $9.72M of principal
.
Largest 10 bondholders include OAKTREE CAPITAL MANAGEMENT LP ($9.51M of principal), UBS ASSET MANAGEMENT AMERICAS INC ($200K of principal), Congress Wealth Management LLC / DE / ($10K of principal), WEDBUSH SECURITIES INC ($3K of principal), GAMCO INVESTORS, INC. ET AL ($0 of principal), Raymond James Financial Services Advisors, Inc. ($0 of principal), LPL Financial LLC ($0 of principal), Merit Financial Group, LLC ($0 of principal), CITIGROUP INC ($0 of principal), and Atlas Merchant Capital LLC ($0 of principal).
This table shows the top 4 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.